Search

Your search keyword '"Sasaki, Hidenori"' showing total 214 results
Start Over Author "Sasaki, Hidenori"
214 results on '"Sasaki, Hidenori"'

1. Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology

Author

Murakami, Michiyasu, Miyata, Yoshiharu, Nakashima, Kazuhisa, Abe, Masakazu, Nishimura, Junichi, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakamura, Naoki, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Okita, Kenji, Yamamoto, Nobuyuki, Aogi, Kenjiro, and Nakajima, Takako Eguchi

Published
2025
Full Text
View/download PDF

2. Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

Author

Nakashima, Kazuhisa, Harashima, Saki, Kaneko, Rena, Tanaka, Ryuhei, Abe, Masakazu, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-il, Satomi, Eriko, Takeda, Masayuki, Nakajima, Takako Eguchi, Nakamura, Naoki, Nishimura, Junichi, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Okita, Kenji, Yamamoto, Nobuyuki, Aogi, Kenjiro, and Sasaki, Hidenori

Published
2025
Full Text
View/download PDF

3. Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

Author

Nakashima, Kazuhisa, Yokomizo, Ayako, Murakami, Michiyasu, Okita, Kenji, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakajima, Takako Eguchi, Nakamura, Naoki, Nishimura, Junichi, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Yamamoto, Nobuyuki, Aogi, Kenjiro, and Abe, Masakazu

Published
2024
Full Text
View/download PDF

4. Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology

Author

Yokomizo, Ayako, Nakashima, Kazuhisa, Iba, Arisa, Okita, Kenji, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-Il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakajima, Takako Eguchi, Nakamura, Naoki, Nishimura, Junichi, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Yamamoto, Nobuyuki, Aogi, Kenjiro, and Abe, Masakazu

Published
2024
Full Text
View/download PDF

5. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

Author

Hayashi, Toshinobu, Yamamoto, Shun, Miyata, Yoshiharu, Takeda, Masayuki, Abe, Masakazu, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-Il, Sasaki, Hidenori, Satomi, Eriko, Tanaka, Ryuhei, Nakajima, Takako Eguchi, Nakamura, Naoki, Nishimura, Junichi, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Okita, Kenji, Yamamoto, Nobuyuki, Aogi, Kenjiro, and Iihara, Hirotoshi

Published
2024
Full Text
View/download PDF

6. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis

Author

Iihara, Hirotoshi, Abe, Masakazu, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-Il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakajima, Takako Eguchi, Nakamura, Naoki, Nishimura, Junichi, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Okita, Kenji, Yamamoto, Nobuyuki, and Aogi, Kenjiro

Published
2024
Full Text
View/download PDF

7. Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023

Author

Kobayashi, Masamitsu, Kako, Jun, Iba, Arisa, Okuyama, Ayako, Ozawa, Keiko, Abe, Masakazu, Wada, Makoto, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K., Kim, Yong-Il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakajima, Takako Eguchi, Nakamura, Naoki, Nishimura, Junichi, Noda, Mayumi, Hayashi, Kazumi, Higashi, Takahiro, Boku, Narikazu, Matsumoto, Koji, Matsumoto, Yoko, Okita, Kenji, Yamamoto, Nobuyuki, Aogi, Kenjiro, and Iino, Keiko

Published
2024
Full Text
View/download PDF

8. Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology

Author

Murakami, Michiyasu, Miyata, Yoshiharu, Nakashima, Kazuhisa, Abe, Masakazu, Nishimura, Junichi, Wada, Makoto, Iino, Keiko, Akechi, Tatsuo, Iihara, Hirotoshi, Imamura, Chiyo K., Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-il, Sasaki, Hidenori, Satomi, Eriko, Takeda, Masayuki, Tanaka, Ryuhei, Nakamura, Naoki, Noda, Mayumi, and Hayashi, Kazumi

Subjects
ACUTE phase reaction, MEDICAL sciences, OLANZAPINE, DRUG prices, ANTIPSYCHOTIC agents
Abstract

Background: Olanzapine is an atypical antipsychotic drug used for chemotherapy-induced nausea and vomiting. It is particularly effective in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy (HEC). However, it has side effects, such as hyperglycemia and somnolence, the efficacy and safety of adding olanzapine to triplet antiemetic therapy (5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone) must be verified. Methods: We performed a systematic review and meta-analysis to compare the effectiveness of olanzapine combined with triplet antiemetic therapy and triplet antiemetic therapy in preventing nausea and vomiting for HEC. We set five items (hyperglycemia, prevention of vomiting, prevention of nausea, adverse events, and cost (drug costs)) as outcomes and conducted a systematic review. Results: Five randomized controlled trials was extracted and they showed that the addition of olanzapine was effective in control of nausea and vomiting, especially in the delayed phase. Complete response of acute and delayed phase were significantly higher in the olanzapine group. Risk difference was − 0.14 [95% CI − 0.26, − 0.03; p = 0.02] and − 0.14 [95% CI − 0.19, −0.09; p < 0.00001], respectively. Additionally, we evaluated hyperglycemia and somnolence, which are typical side effects of olanzapine. However, the incidence of grade ≥ 2 was low in both events, and there was no significant difference between olanzapine and control groups. Conclusions: Adding olanzapine to triplet antiemetic therapy is useful in preventing nausea and vomiting induced by HEC and there would be minimal adverse effects from the combination use. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

11. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study

Author

Yonekura, Kentaro, Kusumoto, Shigeru, Choi, Ilseung, Nakano, Nobuaki, Ito, Asahi, Suehiro, Youko, Imaizumi, Yoshitaka, Yoshimitsu, Makoto, Nosaka, Kisato, Ohtsuka, Eiichi, Hidaka, Michihiro, Jo, Tatsuro, Sasaki, Hidenori, Moriuchi, Yukiyoshi, Ogata, Masao, Tatetsu, Hiro, Ishitsuka, Kenji, Miyazaki, Yasushi, Ueda, Ryuzo, Utsunomiya, Atae, and Ishida, Takashi

Published
2020
Full Text
View/download PDF

12. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

Author

Aogi, Kenjiro, Takeuchi, Hideki, Saeki, Toshiaki, Aiba, Keisuke, Tamura, Kazuo, Iino, Keiko, Imamura, Chiyo K., Okita, Kenji, Kagami, Yoshikazu, Tanaka, Ryuhei, Nakagawa, Kazuhiko, Fujii, Hirofumi, Boku, Narikazu, Wada, Makoto, Akechi, Tatsuo, Iihara, Hirotoshi, Ohtani, Shoichiro, Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-Il, Sasaki, Hidenori, Shima, Yasuo, Takeda, Masayuki, Nagasaki, Eijiro, Nishidate, Toshihiko, Higashi, Takahiro, and Hirata, Kouichi

Published
2021
Full Text
View/download PDF

13. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial

Author

Kurosawa, Mitsutoshi, Yamagishi, Kayo, Kobayashi, Naoki, Minauchi, Koichiro, Harigae, Hideo, Fukuhara, Noriko, Takahashi, Naoto, Kameoka, Yoshihiro, Matsuda, Shin, Saitoh, Yurie, Tsukamoto, Norifumi, Yokohama, Akihiko, Kubota, Nobuko, Minami, Yosuke, Yamauchi, Nobuhiko, Kumagai, Kyoya, Tsujimura, Hideki, Izutsu, Koji, Maruyama, Dai, Takayama, Nobuyuki, Ohyashiki, Kazuma, Akahane, Daigo, Shimoyama, Tatsu, Shimada, Takaki, Kamiyama, Yutaro, Dobashi, Nobuaki, Wasada, Izumi, Sano, Fumiaki, Takimoto, Madoka, Chou, Takaaki, Ishiguro, Takuro, Masaki, Yasufumi, Yamauchi, Takahiro, Ono, Takaaki, Yamamoto, Kazuhito, Kato, Harumi, Tokunaga, Takashi, Shimada, Kazuyuki, Ushijima, Yoko, Iida, Shinsuke, Kusumoto, Shigeru, Uchida, Toshiki, Hanamura, Ichiro, Kanasugi, Jo, Kagami, Yoshitoyo, Hiraga, Junji, Miyazaki, Kana, Utsumi, Takahiko, Kuroda, Junya, Kobayashi, Tsutomu, Matsumura, Itaru, Rai, Shinya, Murayama, Tohru, Gomyo, Hiroshi, Sunami, Kazutaka, Makita, Masanori, Ichinohe, Tatsuo, Fukushima, Noriyasu, Yoshida, Isao, Yakushijin, Yoshihiro, Asai, Hiroaki, Suehiro, Youko, Choi, Ilseung, Takamatsu, Yasushi, Sasaki, Hidenori, Yamasaki, Satoshi, Tsukada, Junichi, Morimoto, Hiroaki, Kimura, Shinya, Yokoo, Masako, Yoshida, Shinichiro, Moriuchi, Yukiyoshi, Miyazaki, Yasushi, Imaizumi, Yoshitaka, Jo, Tatsuro, Nosaka, Kisato, Tatetsu, Hiro, Hidaka, Michihiro, Harada, Naoko, Ohtsuka, Eiichi, Ishitsuka, Kenji, Yoshimitsu, Makoto, Utsunomiya, Atae, Takatsuka, Yoshifusa, Morishima, Satoko, Nakachi, Sawako, Watanabe, Takashi, Tobinai, Kensei, Wakabayashi, Masashi, Morishima, Yasuo, Kobayashi, Hirofumi, Kinoshita, Tomohiro, Suzuki, Takayo, Yamaguchi, Motoko, Ando, Kiyoshi, Ogura, Michinori, Taniwaki, Masafumi, Uike, Naokuni, Yoshino, Tadashi, Nawano, Sigeru, Terauchi, Takashi, Hotta, Tomomitsu, Nagai, Hirokazu, and Tsukasaki, Kunihiro

Published
2018
Full Text
View/download PDF

19. Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia–lymphoma

Author

Hiramatsu, Hiroaki, primary, Nosaka, Kisato, additional, Kusumoto, Shigeru, additional, Nakano, Nobuaki, additional, Choi, Ilseung, additional, Yoshimitsu, Makoto, additional, Imaizumi, Yoshitaka, additional, Hidaka, Michihiro, additional, Sasaki, Hidenori, additional, Makiyama, Junya, additional, Ohtsuka, Eiichi, additional, Jo, Tatsuro, additional, Ogata, Masao, additional, Ito, Asahi, additional, Yonekura, Kentaro, additional, Tatetsu, Hiro, additional, Kato, Takeharu, additional, Kawakita, Toshiro, additional, Suehiro, Youko, additional, Ishitsuka, Kenji, additional, Iida, Shinsuke, additional, Matsutani, Takaji, additional, Nishikawa, Hiroyoshi, additional, Utsunomiya, Atae, additional, Ueda, Ryuzo, additional, and Ishida, Takashi, additional

Published
2022
Full Text
View/download PDF

20. Topology Optimization With Shapley Additive Explanations for Permanent Magnet Synchronous Motors

Author

Sasaki, Hidenori and Yamamura, Koichi

Abstract

This study proposes a novel methodology for topology optimization, employing an explainable deep neural network (XDNN). This innovative approach utilizes Shapley additive explanations (SHAPs), a tool designed to elucidate the predictive reasoning of convolutional neural networks (CNNs). The contributing regions to the characteristics are revealed by SHAP and topology optimization is performed in restricted regions to reduce the computational cost during the search while ensuring an efficient search. As a practical demonstration of the efficacy of the proposed method, it is applied to an interior permanent magnet synchronous motor. The results comprehensively demonstrate the effectiveness and potential implications of the novel methodology.

Published
2024
Full Text
View/download PDF

21. Generalization Performance in Predicting Torque Characteristics Using Convolutional Neural Network and Stator Magnetic Flux

Author

Iwata, Kazuhisa, Sasaki, Hidenori, Igarashi, Hajime, Nakagawa, Daisuke, and Ueda, Tomoya

Abstract

This study proposes a novel approach using convolutional neural networks (CNNs) to predict the torque characteristics of an interior permanent magnet (IPM) motor. The proposed method allows CNNs to predict the average torque and torque amplitude under various magnet configurations using the magnetic flux density distribution of the stator core. The proposed method, compared with methods trained only on the magnetic flux density distributions of the rotor core, improves the generalization performance in predicting torque characteristics. This significantly reduces the training data. In addition, the topology optimization (TO) time using the proposed method is reduced by 45% compared with the conventional method that only utilizes the finite element method (FEM).

Published
2024
Full Text
View/download PDF

22. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary

Author

Takeuchi, Hideki, Saeki, Toshiaki, Aiba, Keisuke, Tamura, Kazuo, Aogi, Kenjiro, Eguchi, Kenji, Okita, Kenji, Kagami, Yoshikazu, Tanaka, Ryuhei, Nakagawa, Kazuhiko, Fujii, Hirofumi, Boku, Narikazu, Wada, Makoto, Akechi, Tatsuo, Udagawa, Yasuhiro, Okawa, Yutaka, Onozawa, Yusuke, Sasaki, Hidenori, Shima, Yasuo, Shimoyama, Naohito, Takeda, Masayuki, Nishidate, Toshihiko, Yamamoto, Akifumi, Ikeda, Tadashi, and Hirata, Koichi

Published
2016
Full Text
View/download PDF

27. Prediction of IPM Machine Torque Characteristics Using Deep Learning Based on Magnetic Field Distribution

Author

Sasaki, Hidenori, Hidaka, Yuki, Igarashi, Hajime, Sasaki, Hidenori, Hidaka, Yuki, and Igarashi, Hajime

Abstract

This paper proposes a new method for accurately predicting rotating machine properties using a deep neural network (DNN). In this method, the magnetic field distribution over a cross-section of a rotating machine at a fixed mechanical angle is used as the input data for the DNN. The prediction accuracy of the torque properties of an inner permanent magnet (IPM) motor for the CNNs trained by the magnetic flux density distribution and material configuration is compared. It is shown that the proposed method facilitates a more accurate prediction of machine performance than a conventional method in which the cross-sectional image of a rotating machine is input to the DNN. Furthermore, the DNN learned by the proposed method is applied to the topology optimization algorithm. Topology optimization can be effectively accelerated because the number of analyses by the finite element method can be reduced using the proposed method. The total computing cost is reduced by 52.5% compared with conventional optimization without surrogate models.

Published
2022

28. Prediction of Current-Dependent Motor Torque Characteristics Using Deep Learning for Topology Optimization

Author

Aoyagi, Taiga, Otomo, Yoshitsugu, Igarashi, Hajime, Sasaki, Hidenori, Hidaka, Yuki, Arita, Hideaki, Aoyagi, Taiga, Otomo, Yoshitsugu, Igarashi, Hajime, Sasaki, Hidenori, Hidaka, Yuki, and Arita, Hideaki

Abstract

In this study, we propose a fast topology optimization (TO) method based on a deep neural network (DNN) that predicts the current-dependent motor torque characteristics using its cross-sectional image. The trained DNN is shown to provide the current condition that provides the maximum torque under the assumed motor control method. The proposed method helps perform TO with a reduced number of field computations while maintaining a high search capability.

Published
2022

31. Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab

Author

Nosaka, Kisato, primary, Kusumoto, Shigeru, additional, Nakano, Nobuaki, additional, Choi, Ilseung, additional, Yoshimitsu, Makoto, additional, Imaizumi, Yoshitaka, additional, Hidaka, Michihiro, additional, Sasaki, Hidenori, additional, Makiyama, Junya, additional, Ohtsuka, Eiichi, additional, Jo, Tatsuro, additional, Ogata, Masao, additional, Ito, Asahi, additional, Yonekura, Kentaro, additional, Tatetsu, Hiro, additional, Kato, Takeharu, additional, Kawakita, Toshiro, additional, Suehiro, Youko, additional, Ishitsuka, Kenji, additional, Iida, Shinsuke, additional, Matsutani, Takaji, additional, Utsunomiya, Atae, additional, Ueda, Ryuzo, additional, and Ishida, Takashi, additional

Published
2021
Full Text
View/download PDF

32. Focal segmental glomerulosclerosis and concurrent glomerular microangiopathy after long-term imatinib administration

Author

Morita, Natsumi, primary, Ozaki, Tomomi, additional, Yokota, Soichiro, additional, Sasaki, Hidenori, additional, Watanabe, Maho, additional, Takahashi, Koji, additional, Himuro, Naoko, additional, Ito, Kenji, additional, Yasuno, Tetsuhiko, additional, Miyake, Katsuhisa, additional, Nawata, Aya, additional, Nakayama, Toshiyuki, additional, Uesugi, Noriko, additional, and Masutani, Kosuke, additional

Published
2021
Full Text
View/download PDF

33. Impact of Mogamulizumab-Containing Chemotherapy on HBV Reactivation in Patients with T-Cell Lymphoma: A Multicenter Retrospective Observational Study (PROACTIVE-MOGA)

Author

Nosaka, Kisato, Kusumoto, Shigeru, Imaizumi, Yoshitaka, Hashimoto, Hiroya, Makiyama, Junya, Yoshimitsu, Makoto, Kato, Takeharu, Sasaki, Hidenori, Suehiro, Youko, Koh, Ki-Ryang, Kawamata, Toyotaka, Miyakawa, Toshikazu, Takatsuka, Yoshifusa, Sato, Takayuki, Shirouchi, Yuko, Kato, Koji, Izutsu, Koji, Murayama, Tohru, Higashi, Takehiro, Iwasaki, Hiromi, Kosugi, Satoru, Uchiyama, Hitoji, Tsukasaki, Kunihiro, Yamashita, Yusuke, Ogasawara, Fumiya, Sakaida, Emiko, Shindo, Takero, Yakushijin, Kimikazu, Akizuki, Keiichi, Etoh, Ken-ichiro, Kawano, Noriaki, Igarashi, Tetsuyuki, Fukuhara, Noriko, Nakamura, Nobuhiko, Yoshida, Isao, Nakano, Nobuaki, Yoshizumi, Tomoharu, and Mizokami, Masashi

Published
2023
Full Text
View/download PDF

42. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

Author

Aogi, Kenjiro, primary, Takeuchi, Hideki, additional, Saeki, Toshiaki, additional, Aiba, Keisuke, additional, Tamura, Kazuo, additional, Iino, Keiko, additional, Imamura, Chiyo K., additional, Okita, Kenji, additional, Kagami, Yoshikazu, additional, Tanaka, Ryuhei, additional, Nakagawa, Kazuhiko, additional, Fujii, Hirofumi, additional, Boku, Narikazu, additional, Wada, Makoto, additional, Akechi, Tatsuo, additional, Iihara, Hirotoshi, additional, Ohtani, Shoichiro, additional, Okuyama, Ayako, additional, Ozawa, Keiko, additional, Kim, Yong-Il, additional, Sasaki, Hidenori, additional, Shima, Yasuo, additional, Takeda, Masayuki, additional, Nagasaki, Eijiro, additional, Nishidate, Toshihiko, additional, Higashi, Takahiro, additional, and Hirata, Kouichi, additional

Published
2020
Full Text
View/download PDF

44. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice

Author

Tanaka, Toshihiro, Ueno, Miho, Nakashima, Yuta, Chinen, Shotaro, Sato, Eiichi, Masaki, Michio, Mogi, Ai, Sasaki, Hidenori, Tamura, Kazuo, and Takamatsu, Yasushi

Subjects
Adult, post‐treatment therapy, Antineoplastic Agents, Breast Neoplasms, Original Articles, Ketones, Middle Aged, Disease-Free Survival, Drug Administration Schedule, clinical practice, Treatment Outcome, Chemotherapy, Humans, Original Article, Female, metastatic breast cancer, Neoplasm Metastasis, Furans, eribulin, Aged, Retrospective Studies
Abstract

Background Evidence of eribulin therapy for metastatic breast cancer (MBC) in clinical practice is not well documented. Methods We retrospectively analyzed the safety and efficacy of eribulin in 29 MBC patients from 2011 to 2016 at Fukuoka University Hospital. Results The median patient age, number of courses, total dose, and relative dose intensity were as follows: 65 years, five courses, 8.6 mg/m2, and 75%, respectively. One patient achieved a complete response, (CR) six a partial response (PR), eight stable disease (SD) and 14 patients exhibited progressive disease. The objective response rate (ORR: CR + PR) was 24.1%, and the clinical benefit rate (CBR: CR + PR + SD) was 51.7%. The median progression‐free survival was 90 days (95% confidence interval [CI] 67–126) and median overall survival was 264 days (95% CI 198–357). In patients who previously received 2–4 regimens, the ORR was 28.5% and the CBR was 57.1%. In patients who received 5–12 regimens, the ORR was 20% and the CBR was 45%. Chemotherapy was administered to 20 patients (69%) after eribulin administration, and the median overall survival rate of cases that achieved greater than a PR was 1088 days. The most frequent treatment‐related grade 3/4 adverse events were neutropenia (55.2%), and febrile neutropenia (20.1%). Grade 3 peripheral neuropathy occurred in 13.8% of patients, but was not exacerbated even if present before treatment. Conclusion Eribulin is effective for MBC patients who have received multiple chemotherapies. Neutropenia and febrile neutropenia may develop after heavy prior therapy.

Published
2017

46. Clinical significance of the immunoglobulin G heavy‐chain repertoire in peripheral blood mononuclear cells of adult T‐cell leukaemia–lymphoma patients receiving mogamulizumab.

Author

Nosaka, Kisato, Kusumoto, Shigeru, Nakano, Nobuaki, Choi, Ilseung, Yoshimitsu, Makoto, Imaizumi, Yoshitaka, Hidaka, Michihiro, Sasaki, Hidenori, Makiyama, Junya, Ohtsuka, Eiichi, Jo, Tatsuro, Ogata, Masao, Ito, Asahi, Yonekura, Kentaro, Tatetsu, Hiro, Kato, Takeharu, Kawakita, Toshiro, Suehiro, Youko, Ishitsuka, Kenji, and Iida, Shinsuke

Subjects
MONONUCLEAR leukocytes, IMMUNOGLOBULIN G, T cells, B cells
Abstract

Summary: 'Monitoring of immune responses following mogamulizumab‐containing treatment in patients with adult T‐cell leukaemia–lymphoma (ATL)' (MIMOGA) is a multicentre prospective clinical study (UMIN000008696). In the MIMOGA study, we found that a lower percentage of CD2−CD19+ B cells in peripheral blood mononuclear cells (PBMC) was a significant unfavourable prognostic factor for overall survival (OS). Accordingly, we then analysed the immunoglobulin G (IgG) heavy‐chain repertoire in PBMC by high‐throughput sequencing. Of the 101 patients enrolled in the MIMOGA study, for 81 a sufficient amount of PBMC RNA was available for repertoire sequencing analysis. Peripheral IgG B cells in patients with ATL had a restricted repertoire relative to those in healthy individuals. There was a significant positive correlation between the Shannon–Weaver diversity index (SWDI) for the IgG repertoire and proportions of B cells in the PBMC of the patients. Multivariate analysis identified two variables significantly affecting OS: a higher serum soluble interleukin‐2 receptor level, and a lower SWDI for the IgG repertoire [hazard ratio, 2·124; 95% confidence interval, 1·114–4·049; n = 44]. The present study documents the importance of humoral immune responses in patients receiving mogamulizumab‐containing treatment. Further investigation of strategies to enhance humoral immune responses in patients with ATL is warranted. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results